A longer view of great investors SEC filings
Menu
Companies/Definium Therapeutics Inc

Company research

Definium Therapeutics Inc

DFTX

Current Tracked Holder
1
Purchases 0 $0
Sales 17 $7.0M

Price history loads when this section approaches view.

Quarter-End Change Analysis

No published quarterly analysis yet

Reviewed research will appear here when it is published.

Current reported holders

Portfolio ManagerRecent activitySharesValuePortfolio
Stanley DruckenmillerDuquesne Family Office LLC
DFTXNew
356,600
$16,774,000
0.32%

Long-term company research

Fundamental analysis

Research pending

Fundamental research pending

Reviewed company research will appear here when available.

Financial data loads when this section approaches view.

Insider activity

1-year insider activity

Open-market purchases and sales only.

Checked 2026-10-02
DateInsiderTypeSharesPriceValueSource
2026-09-25Karlin DanielDirector, Chief Medical OfficerSale10,853$37$396,894SEC ↗
2026-09-25Barrow RobertDirector, Chief Executive OfficerSale31,550$37$1.2MSEC ↗
2026-09-25Wiley Matthew T.Chief Commercial OfficerSale3,097$37$113,257SEC ↗
2026-09-25Sullivan MarkChief Legal OfficerSale14,051$37$513,845SEC ↗
2026-09-25Roberts BrandiChief Financial OfficerSale3,377$37$123,497SEC ↗
2026-09-03Barrow RobertSale19,023$38$721,733SEC ↗
2026-06-25Sullivan MarkSale13,008$45$585,750SEC ↗
2026-06-25Karlin DanielSale10,035$45$451,876SEC ↗
2026-06-25Roberts BrandiSale3,013$45$135,675SEC ↗
2026-06-25Barrow RobertSale29,208$45$1.3MSEC ↗